Format
Sort by
Items per page

Send to

Choose Destination

Links from Protein

Items: 1 to 20 of 1131

1.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761
2.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F.

Eur J Cancer. 2017 Dec;87:131-139. doi: 10.1016/j.ejca.2017.10.016. Epub 2017 Nov 14.

3.

Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.

Tang XL, Yan L, Zhu L, Jiao DM, Chen J, Chen QY.

J Pharmacol Sci. 2017 Sep;135(1):1-7. doi: 10.1016/j.jphs.2017.06.006. Epub 2017 Sep 6.

4.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA; Lungscape Consortium.

Lung Cancer. 2017 Sep;111:143-149. doi: 10.1016/j.lungcan.2017.07.021. Epub 2017 Jul 22.

PMID:
28838386
5.

Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.

Xu CW, Wang WX, Wu MJ, Zhu YC, Zhuang W, Lin G, Du KQ, Huang YJ, Chen YP, Chen G, Fang MY.

Thorac Cancer. 2017 Sep;8(5):417-422. doi: 10.1111/1759-7714.12455. Epub 2017 Jun 7.

6.

Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases.

Lorenzon L, Ricca L, Pilozzi E, Lemoine A, Riggio V, Giudice MT, Mallel G, Fochetti F, Balducci G.

Pathol Res Pract. 2017 Aug;213(8):1002-1009. doi: 10.1016/j.prp.2017.04.013. Epub 2017 Apr 21.

PMID:
28559118
7.

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A.

Virchows Arch. 2017 Jul;471(1):49-55. doi: 10.1007/s00428-017-2131-1. Epub 2017 May 20.

PMID:
28528511
8.

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.

Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR.

J Thorac Oncol. 2017 Aug;12(8):1233-1246. doi: 10.1016/j.jtho.2017.04.031. Epub 2017 May 10.

PMID:
28502721
9.

The c-Met receptor: Implication for targeted therapies in colorectal cancer.

Safaie Qamsari E, Safaei Ghaderi S, Zarei B, Dorostkar R, Bagheri S, Jadidi-Niaragh F, Somi MH, Yousefi M.

Tumour Biol. 2017 May;39(5):1010428317699118. doi: 10.1177/1010428317699118. Review.

PMID:
28459362
10.

Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.

Yasui H, Ohnishi Y, Nakajima M, Nozaki M.

Oncol Rep. 2017 Jun;37(6):3674-3680. doi: 10.3892/or.2017.5587. Epub 2017 Apr 19.

PMID:
28440510
11.

The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.

Kim WY, Shim SH, Jung HY, Dong M, Kim SN, Lee SJ.

Hum Pathol. 2017 Jun;64:98-105. doi: 10.1016/j.humpath.2017.04.002. Epub 2017 Apr 17.

PMID:
28428108
12.

The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review.

Chen S, Zhu Y, Cui J, Wang Y, Xia Y, Song J, Cheng S, Zhou C, Zhang D, Zhang B, Shi B.

Urol Oncol. 2017 Aug;35(8):532.e15-532.e23. doi: 10.1016/j.urolonc.2017.03.027. Epub 2017 Apr 18. Review.

PMID:
28427859
13.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M.

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

14.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.

Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ, Chuai S, Zhang Q, Xie Z, Gao H, Chen H, Wang Z, Wang Z, Yang XN, Wang BC, Gan B, Chen ZH, Jiang BY, Wu SP, Liu SY, Xu CR, Wu YL.

Clin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10.

PMID:
28396313
15.

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.

Salgia R.

Mol Cancer Ther. 2017 Apr;16(4):555-565. doi: 10.1158/1535-7163.MCT-16-0472. Review.

16.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

17.

Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.

Pei J, Chu T, Shao M, Teng J, Sha H, Gu A, Li R, Qian J, Mao W, Li Y, Han B.

Yonsei Med J. 2017 May;58(3):581-591. doi: 10.3349/ymj.2017.58.3.581.

18.

MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma.

Suryavanshi M, Shah A, Kumar D, Panigrahi MK, Metha A, Batra U.

Oncol Res Treat. 2017;40(4):198-202. doi: 10.1159/000457801. Epub 2017 Mar 8.

19.

MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.

Song Z, Wang X, Zheng Y, Su H, Zhang Y.

Clin Lung Cancer. 2017 Mar;18(2):213-219.e2. doi: 10.1016/j.cllc.2016.09.011. Epub 2016 Oct 5.

PMID:
28322191
20.

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.

Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.

Lung Cancer. 2017 Apr;106:131-137. doi: 10.1016/j.lungcan.2017.02.008. Epub 2017 Feb 16.

PMID:
28285687

Supplemental Content

Support Center